Randomized controlled trial evaluates lurasidone vs placebo for cognitive function in euthymic bipolar patients, indicating its potential role in therapy.
Key Points
Lurasidone significantly improves cognitive function in euthymic patients with bipolar disorder.
The primary outcome assessed was changes in cognitive scores over time using the ISBD-BANC measure.
Analysis involved 100 patients randomized to lurasidone or placebo across multiple countries including Canada and Japan.
This provides novel insights into 5-HT7 receptor antagonists' effects on cognition in bipolar disorder.